BACKGROUND: According to the 2012 ISHLT Registry, two-thirds of patients at the time of transplant do not have circulating antibodies. For these non-sensitized patients, the incidence of post-transplant de novo antibody production has not been firmly established. Its impact on outcome in patients on routine triple drug immunosuppression has also not been determined.
METHODS: Between 2006 and 2011, we evaluated 133 non-sensitized heart transplant patients for the development of de novo circulating antibodies [both nonspecific and donor-specific antibodies (DSA)] in the first year after transplant. Blood for detection of circulating antibodies are routinely drawn at 1,3,6,12 months after heart transplant. Post-transplant outcomes assessed included 3-year survival, freedom from cardiac allograft vasculopathy (CAV), 1-year treated cellular rejection (CR) and antibody-mediated rejection (AMR).
RESULTS: Of the 133 non-sensitized heart transplant patients, the development of non-specific antibodies was detected in 29 (22%) patients, DSA in 10 (7.5%) patients and no antibodies in 94 (70.5%) patients. Patients with first-year DSA had significantly lower survival and a trend for less freedom from CAV. The DSA and non-specific antibody groups had less freedom from first-year treated AMR.
|Outcomes||No Ab (n=94)||Non-Specific Ab (n=29]||DSA (n=10]||Log-Rank p-value|
|3-Year Actuarial Survival||93%||93%||50%||<0.0001|
|3-Year Freedom from CAV||84%||96%||70%||0.076|
|1-Year Freedom from Any-Treated CR||92%||90%||90%||0.970|
|1-Year Freedom from Any-Treated AMR||100%||90%||90%||0.007|
CONCLUSION: Non-sensitized pre-transplant patients who developed first year DSA after transplant have poor outcome. Treatment of these patients with anti-humoral therapies appears warranted, but merits a randomized trial.
Reinsmoen, N.: Speaker’s Bureau, One Lambda.
To cite this abstract in AMA style:Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Patel J. Poor Outcome in Non-Sensitized Patients Developing De Novo Circulating Antibodies after Heart Transplantation [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/poor-outcome-in-non-sensitized-patients-developing-de-novo-circulating-antibodies-after-heart-transplantation/. Accessed July 3, 2020.
« Back to 2013 American Transplant Congress